The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
Introduction: Osteoporosis is highly prevalent in patients with rheumatoid arthritis (RA) and is a frequent cause of fractures, disability, reduced quality of life and increased use of healthcare resources.
Discussion: Factors associated with the development of osteoporosis and fractures in patients with RA include disease activity, inflammation, gender, age, low body mass and glucocorticoid exposure. Several processes contribute towards the pathology of RA-associated osteoporosis, and increased osteoclast activation and subsequent bone resorption mediated by pro-inflammatory cytokines are thought to play major roles. Given the key effects of interleukin-6 (IL-6) in both RA and osteoporosis, and its ability to modulate other inflammatory mediators, IL-6 may be an important factor specifically associated with osteoporosis in patients with RA.
Conclusion: The development of agents that modulate the actions of IL-6 and those of other pro-inflammatory mediators of bone loss may provide alternative osteoporosis management strategies for patients with RA than existing general osteoporosis therapies.
cytokines, interleukin-6, osteoporosis, rheumatoid arthritis
Edwards, C.J.
dcb27fec-75ea-4575-a844-3588bcf14106
Williams, E.
a06b8350-5be8-478c-a0ce-573e7fecfcd7
14 March 2010
Edwards, C.J.
dcb27fec-75ea-4575-a844-3588bcf14106
Williams, E.
a06b8350-5be8-478c-a0ce-573e7fecfcd7
Edwards, C.J. and Williams, E.
(2010)
The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.
Osteoporosis International.
(doi:10.1007/s00198-010-1192-7).
Abstract
Introduction: Osteoporosis is highly prevalent in patients with rheumatoid arthritis (RA) and is a frequent cause of fractures, disability, reduced quality of life and increased use of healthcare resources.
Discussion: Factors associated with the development of osteoporosis and fractures in patients with RA include disease activity, inflammation, gender, age, low body mass and glucocorticoid exposure. Several processes contribute towards the pathology of RA-associated osteoporosis, and increased osteoclast activation and subsequent bone resorption mediated by pro-inflammatory cytokines are thought to play major roles. Given the key effects of interleukin-6 (IL-6) in both RA and osteoporosis, and its ability to modulate other inflammatory mediators, IL-6 may be an important factor specifically associated with osteoporosis in patients with RA.
Conclusion: The development of agents that modulate the actions of IL-6 and those of other pro-inflammatory mediators of bone loss may provide alternative osteoporosis management strategies for patients with RA than existing general osteoporosis therapies.
This record has no associated files available for download.
More information
Published date: 14 March 2010
Keywords:
cytokines, interleukin-6, osteoporosis, rheumatoid arthritis
Identifiers
Local EPrints ID: 141510
URI: http://eprints.soton.ac.uk/id/eprint/141510
ISSN: 0937-941X
PURE UUID: 37f11ff5-92a0-4faa-ad51-ce4a44e3c2a1
Catalogue record
Date deposited: 29 Mar 2010 14:05
Last modified: 14 Mar 2024 00:37
Export record
Altmetrics
Contributors
Author:
E. Williams
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics